Great. Good afternoon, everyone. I am Alex Thompson, Managing Director at Stifel. Very happy to have you with us today. We have Greg Moss, Chief Business and Legal Officer, and Jeegar Patel, Chief Scientific Officer. Maybe, Greg, if you want to give a quick overview of the company, and then we will get into a Q&A.
Sure. Evommune has always set out to be a meaningful player in the inflammatory disease space. To that end, we are moving forward a portfolio of programs targeting unique mechanisms and across a number of different modalities. At the moment, we are leading with EVO301, that is our IL-18 binding protein fusion protein. That is going to be entering a phase II-B study in atopic dermatitis in mid-next year. In addition, we are also doing a phase II-A study of that program in ulcerative colitis, and that is set to start at the beginning of next year. We also have EVO756, that is our MRGPRX2 antagonist. That program is solely being studied at the moment in migraine. Before that, we looked at it in subcutaneous diseases, designed studies to get to outcomes.
Unfortunately, didn't see what we wanted to see, but have bounced back and are looking forward to seeing that migraine data, and that will be available end of 2027. In addition, we are moving forward EVO646, that is a TLR7/8 small molecule that will be in a phase one study with a full biomarker plan next year, and that will have data towards the end of 2027. Last week, we announced that we have in-licensed a new program out of China. We will talk a little bit more about that later. That is a VAV1 molecular glue degrader, a really exciting program that is in its final stages of getting ready to start a phase one study. The phase one study will start in December or January. We plan to have data with that program and a full biomarker plan by the middle of next year.
Our entire hypothesis has been built around the idea that you need to manage a portfolio of programs, and we are always thinking about it from three separate and unique perspectives. The one is, does the biology support the hypothesis? Two, is there a very clear clinical and regulatory pathway? Three, can we study these in indications where not only is there a clear medical need, but is there a commercial opportunity? We think we have got a nice, well-rounded out portfolio that doesn't stop there. We continue to evaluate new opportunities in discovery. We have got a set of STAT6 degraders and inhibitors that we are looking at in discovery, and we look to advance those towards candidate selection next year. We are always being opportunistic as we consider business development and new research opportunities.
At the moment, funded through the end of 2029, and all those catalysts are well-supported by the existing resources.
Great. Yeah. Maybe let's kick things off with IL-18 and that story, because I think it's definitely an emerging target in atopic derm, and you generated some interesting data there. Maybe just set things off to start. Can you talk about where IL-18 sits in the inflammatory cascade and why is it interesting to an orthogonal target in atopic disease, or maybe more broadly?
Yeah, no, absolutely. I think, as we came to IL-18, it's been a target of interest for some time. We had an opportunity to in-license this molecule from a company called AprilBio, which had a unique IL-18 fusion protein. Took advantage of the IL-18 binding protein, which is the natural modulator of IL-18 biology. It's the natural brake that keeps the IL-18 signaling under control. It was fused to a serum albumin Fab that gave it the extended half-life and replacement value on a frequency that's amenable to some of the diseases that we're considering. The IL-18 biology is very interesting. Predominantly found from epithelial cells, dendritic cells, keratinocytes, can be produced in copious amounts in inflammatory diseases, especially in diseases like skin, atopic dermatitis. I think what makes it unique is that it's beyond just Th2 biology.
It's impacting Th2 biology significantly, but it's also impacting Th1, Th17, and Th22 biology as well. We find it very uniquely upstream of all the inflammatory cascades that can impact these inflammatory diseases in a more meaningful way. We look at it as it can expand the efficacy profile that we're seeing with some of the existing therapies that target one or two of those inflammatory cascades.
I think, yeah, I think one of the elements here that has been some focus on more recently is this idea that IL-18 and IL-37 signal through a shared receptor pair. I guess to what extent does IL-37, do we understand, interact with IL-18 binding protein, and is that a risk at all of your mechanism, that you actually are an IL-18 binding protein mimetic?
Yeah, no, absolutely. We're happy with the IL-18 binding protein approach. In our hands, certainly, we've done studies where we've looked at binding kinetics of IL-18 versus IL-1 beta and IL-37, because they're essentially the same family. There's actually no measurable or appreciable binding of 301 with those agents. What's reported in the literature is a bit kind of complex. There are some studies that have been done and reported by academic institutes highlighting IL-37 binding under what I would consider non-physiologic conditions to the IL-18 binding protein. We're talking micromolar or double-digit micromolar concentrations being administered in a rare complex formation, and then highlighting, again, non-quantitative amounts of interaction with the IL-18 binding protein. Those are conditions that people just not see physiologically. Just for reference, the ones that are out there talking about picomolar binding of IL-18 to IL-18 binding protein and double-digit micromolar binding, if any.
with the IL-37. IL-37 does have a role though. It is theā
Sure.
āanti-inflammatory cytokine that does go through the kind of the shared receptor. So where the concern would be is if you're impacting that actual shared receptor biology, and we see no evidence of that.
Yeah. So maybe moving on to kind of the empirical data. Could you talk a little about what we've seen empirically in atopic dermatitis for IL-18 programs, including 301 so far?
Yeah. So, we were fortunate that we had very nice phase IIa data in atopic dermatitis. Nice EASI reductions that are in line with some of the other agents that are out there. What was most compelling about our data was that it was given with only two doses. So dosing only on day one and day 29, with a molecule that does sustain for a period of time. And we looked out at week 12, and we still had efficacy continue to improve-
even at that timeframe. So I think that data was encouraging. We still have considerable opportunity as we go into phase IIb to increase our dose and also to increase our dose frequency, so we plan to do a full dose range-finding study. In that study, we also highlighted that we impacted significant levels of biomarkers, including Th2 cascade biomarkers with TARC, as well as markers of Th1, Th17, Th22. So we're capturing the biology that we saw pre-clinically now in the clinical studies, highlighting the broad impact of this mechanism.
So, where are you at right now with the subcu formulation, and sort of what are the next steps there to moving into the IIb?
Yeah, absolutely. We did do the phase IIa study as well as the healthy volunteer study initially with IV formulation. That allowed us to rapidly get into the clinic and see how this mechanism played out. Obviously always knowing that we needed to go to a subcu formulation. We've now developed that subcu formulation. It's at very high concentration. It gets us to the levels that either mimic or potentially even exceed the levels that we've seen with IV administration, and still allows us to dose that at potentially an every four-week schedule. We've confirmed bioavailability of IV versus subcu in non-human primates, and that looks very favorable as well.
From a competitive perspective, there's IL-18 antibodies out there, IL-18 bispecifics. Where do you see this landscape moving forward in the future?
Yeah, absolutely. I think IL-18 is now kind of noted as a pathway of interest in the atopic dermatitis space and potentially other indications. I think there's been numerous kind of opportunities that have been seen where IL-18 clearly has a role in these diseases from multiple companies. I think what's emerging is, what is that magnitude of impact going to beā
Sure.
āacross these studies? We think we have some of the best data from a phase IIa standpoint, but we also want to see where that expands into as we go forward. With that data in hand, we're now seeing obviously some opportunity around bispecifics and combination plays that other people are also looking at. We do feel like IL-18 is sufficient on its own for diseases like atopic dermatitis. Again, coming back to the biomarkers, where you are still hitting the Th2 cascade fully, that you don't necessarily need, say, an IL-13 on top of it.
But there are other opportunities with more orthogonal pathways to considerā
Sure.
āfrom a combination or co-formulation.
Yeah. I can add, we've spoken to a number of physicians. What's become abundantly clear from their feedback is they like the idea of a monotherapy. It gives them the flexibility to think about different combinations.
Yep.
Certainly, it also allows them to not be limited by the fixed dosing that the bispecifics might offer. That said, to the extent that there is opportunities to co-formulate or co-administer, we think that our molecule is exquisitely clean and safe, so it should allow for that.
Yep. You alluded to, you are moving into a UC study next year as well. What is the level of evidence for IL-18 as a target in ulcerative colitis?
Yeah. The genetics certainly support IL-18's role in ulcerative colitis patients, IBD patients in general. I think that has been strong. Obviously, the mucosal barrier impact of IL-18 is well known, and so what we attempt to play on here is that if you can impact IL-18, you will have a major impact on the barrier function as well, which is still a key area of inflammatory diseases that we need to address. So we look forward to starting that study. For that study, we will do it with an IV formulation, so that helps us rapidly get back into the clinic and move that forward. We think that will be a good proof of concept study to highlight the role of IL-18 in that unique space. We also have animal models of disease highlighting nice impact in those traditional models.
There is a fibrosis component of IL-18 biology that we also want to evaluate. We will not get a full picture of that in the UC study, but pre-clinically, certainly there is an impact on fibrosis that could be very relevant for later studies, potentially in Crohn's and other places.
In broad strokes, what are you thinking about in terms of size and scope of a UC study here?
Yeah. It's not fully determined at this point.
Okay.
But we are looking for a relatively, less than 100-patient study, placebo-controlled.
Yep. So, maybe pivoting to TLR7/8, obviously more data today at ACR for the next-gen TLR7/8 there from Beeline. I'm curious, can you talk a little bit about why this is such an exciting target in SLE and other indications?
Yeah. I think the target's been interesting for some time. We've highlighted that we got into this through our collaboration with Accutar, which is a kind of AI chemistry company. Gave us a very unique molecule with good properties, good potency, once-a-day dosing profile that's currently in IND-enabling studies, and we hope to be in the clinic sometime before the middle of next year. But I think the Beeline data, along with the kind of predecessor data from Merck Serono, with their TLR7/8 molecule, highlighted the role of TLR7/8 in lupus and lupus-like indications. Beeline's data today at ACR kind of solidified that a little bit more in SLE.
Yeah.
I think that data was fairly good quality, especially considering it's an oral molecule in a space that's largely dominated by biologics. Overall, I think the biomarkers is very compelling. These are the same biomarkers that we could have line of sight to in both phase one and phase two, as we try to bridge our dataset to some of theirs.
Yeah, sorry, go ahead.
I was just going to add, I think that lupus, the different variations of lupus, they are indications combined that are large enough to supportā
Sure.
āthe potential for multiple mechanisms, sorry, multiple medicines going after the same mechanism. Obviously, those are areas where there's clinical validity that we are interested in. Our team has historically thought that there's great opportunities in other indications for TLR7/8 modulation. Right now, we're in a great position because we're going to be doing this healthy volunteer study with a full biomarker plan and allow us to take the lead from the science andā
Sure.
āto the extent, Beeline continues to share that data, that's great for us. That was the first time I think you saw such compelling oral data in these indications, and that's to be commended. I think that we're inspired by that to some extent, but also energized to look at it in other indications like MG and others, and TED. There's a potential for us, given our team's development expertise and agility, to hit those hard and fast and get out in front.
So, any notable elements of differentiation sort of at the surface here to talk about relative to the first-gen TLR7/8s?
Well, relative to the first gen, clearly our once-a-day dosing profile gives us edge. I think as we think about competition in the space, it's really the Beeline moleculeā
Yeah.
āthat we market ourselves against. But from the first-gen ones, we think we've got a very clean and exciting target.
Moving into phase one next year, obviously, SLE, maybe related CLE makes a lot of sense. You mentioned a few other indications there. Like you've done, we'll talk about with VAV1, go into a potential first-in-class opportunity. Is that a strategy that you would want to apply here too?
Yeah, absolutely. Jeegar can add on, but I think, again, we'll have a front row seat to what others are doing, and we'll have the ability to consider. But if an opportunity presents itself where we could evaluate this in an indication where, like I said, the biology makes sense and there's a clear kind of clinical and regulatory pathway, that would rise to the top. And then perhaps we could consider as well in parallel looking at one of those diseases where there's already been clinical validation, and perhaps there's, on day one, a higher PTS.
And the science is certainly kind of helping us expand the indication potential of these molecules, right? If you consider the kind of the interferon cascade modulation that you're seeing with TLR7/8-
That's clearly well-known, clearly plays a role in lupus. Obviously, the B cell component is an area of further expansion.
The B-cell modulation potential of TLR7/8 is still in infancy to some extent, but we think that's an area of continued exploration, and that'll help expand the indication list that we'reā
Sure.
āconsidering going into for an oral therapy that, again, was not largely addressed in that space.
Is that something that you can see in phase one PD data clearly?
Yeah.
Moving into clinic next year, will we have phase one data next year as well?
Yeah. We'll have phase one data by the end of next year, and then we look to start potential proof of concept studies around the same timeframe.
Okay. Pivoting to VAV1, I guess maybe can we talk a little bit about that deal and why you like that molecule?
Sure. That was a journey, I'll say that.
Sure.
We looked at about a dozen programs over a 24-month period of time that either claimed to target VAV1 or were targeting VAV1. It was obviously a target that rose to the top of our areas of interest because of its potential to be JAK-like without the safety and tolerability liabilities. But historically, we hadn't found the right platform or approach to targeting it. With the rise of molecular glue degradation and the opportunity there, we began to get very interested in it, and we actually spoke with Monte Rosa. At the time, they're the leader in the space, and they ended up doing a very significant partnership deal with Novartis. We began evaluating and diligencing as much of the landscape as we can. We ended up evaluating over a dozen programs, bringing over half of those in under material transfer agreements and evaluating them in our hands.
Candidly, it was frustrating. Each of these programs kept falling over for different diligence reasons. Majority of them for pharmacological reasons and a smaller subset because of challenges with respect to IP and FTO, largely because they appeared to be analogs of the Monte Rosa molecule. About six months ago, we met with the team from Hinova. Hinova is a Shanghai-listed company based in Chengdu, very experienced team all out of big pharma, Merck and Bayer and Scripps and others. It became clear that they had a very, very high amount of talent in chemistry and this really kind of well-set molecular glue degradation platform. We met with them, we engaged, and we got excited because of two things. One, it appeared that their chemistry was completely novel core. Two, in our hands, it had a higher potency than the Monte Rosa molecule.
Three, it was IND-enabled. The IND is now open here in the U.S. The deal terms were negotiated aggressively. I was advised at the time that there were others around the hoop and have since confirmed that there was some big pharma players that we beat out, so that's always a nice thing to know. Importantly, it was a $20 million upfront, $10 million in warrants, which meant that we were partnering with a company that was going to share in our success, and our success would be their success and vice versa.
We obviously executed that in parallel with the small PIPE transaction last week, which rendered the overall expense net neutral for us, with the $30 million we raised covering the $20 million in the upfront, and then $10 million, which is the first milestone payment that's due, and that's due when we initiate the phase two. Hinova will begin and complete the phase one healthy volunteer study for us, and they will also cost share in the phase II-enabling work. From our perspective, we will work with them to design the right healthy volunteer study, the right biomarker study, and we'll also have an opportunity to potentially look at a small inpatient cohort. That's on track to start late December, early January, and we'll have data on that in mid to late 2027.
Can you walk through kind of the mechanism here and sort of the breadth and sort of I want to walk through kind of why you chose RA as your first indication.
Yeah, no, absolutely. VAV has been known for some time, VAV1 specifically. I think it's been exciting because it is immune cell restricted as opposed to some of the other VAVs and some of the other targets we've considered. We think that's going to have some safety advantage of just focusing on the immune cells. It is downstream of both TCR and BCR signaling as well, which makes it exciting to kind of cover a wider breadth of potential indications that have both of those cell types involved in their disease biology. It's upstream of Rho/Rac, and so it's a guanine exchange factor. Like I said, it's been known for some time, but it just wasn't clear how to target it effectively. You've got to remove it, you've got to remove the scaffolding function.
Molecular glue degradation was kind of an obvious choice, but it was really Monte Rosa that first pioneered this and moved it forward into a phase one study. I think there was also some concern about how to go forward with it. They showed very nice target degradation in the phase one study. They also saw some nice effects on both BCR and TCR signaling in ex vivo stimulation assays. Those are somewhat the benchmarks of what you're going to have to try to go after, and that's how we'll get benchmarked in our phase one study.
As well, in terms of the molecule. I think the other part that was exciting was just the overall breadth of immune cell modulation that you can cover with this mechanism.
Yeah.
That led us to a lot of choices. I mean, there's a multitude of indications that could potentially benefit, somewhat similar to JAKs, where you can go into a wide assortment of indications.
We narrowed to RA specifically because we think there's a clear T-cell and B-cell componentā
Yep.
āof RA and where the market is currently with the existing therapies. We think the risk-benefit in RA patients also fits the VAV molecular glue degradation safety profile that we anticipate, and we think that was important as well. That's not to say that'll be the only indication, but I think that's a good indication for us to first go and see where the potential lies. Obviously, Novartis, Monte Rosa are doing psoriatic arthritis-
as well as Sjƶgren's. We like those indications as well. We'll get a nice opportunity to see their data when it comes out.
I guess one of the long-term questions here, I guess, is safety, right? What gives you confidence that impacting signaling downstream of both the T-cell receptor and B-cell receptor is not going to drive increased infection risk or anything like that?
Yeah, I mean, there's clearly some redundancy in the immune system, and I think how hard you hit it will have a clear impact on it. We do want to get a place where we have a nice dose response, and we understand that-
very carefully. The key risk is obviously infection risk overall. That generally comes with the space as a whole.
Sure.
But this one especially, because you are hitting both the T cell and B cell components. So it's something we'll evaluate carefully as development continues. Monte Rosa did not see any real infection risk in their initial studies, which was encouraging for an industry that's just getting into this space.
Yeah.
But it was a short duration study, and so we'll keep an eye on that as we move forward. These are patient populations that are not kind of adverse to some of these risksā
Sure.
āas well. I think that has to play a role. But yeah, I think overall, I think it should have a potentially good safety profile.
Do you have a sense of if you are going to need to have complete degradation, or is there maybe a threshold or something like that?
Yeah, somewhat unknown. These are very potent molecules. Monte Rosa, with their molecules, showed 95% degradationā
Sure.
āat all dose levels evaluated. We hope to carve out somewhat of a dose response, and we can understand that a little bit more-
carefully. Our starting dose, just to give you some reference point of how active and potent these molecules are, is 0.1 milligrams. That's essentially our starting dose for an oral therapy. We've got good bioavailability, but it also highlights just how potent these molecules are-
in impacting the immune system.
Just to add, I think whilst it's clear that the molecule has dosing potential for QD-
we also see in the animal studies that that degradation lasts for close to seven days.
Yeah.
There's the potential there for us to continue to optimize and gain edge and possibly have a once-a-week drug.
Yeah. One of my big questions in this space generally is oral combos. Could you see a world in which VAV1 and TLR7/8 might make sense synergistically?
I certainly see a pharmacological benefit of having both of those there, but I think it'd also have to be balanced against the potential, kind of what you highlighted earlier, right?
Yeah.
Kind of the overlapping infection risk that potentially can come with that as well. We'll certainly do the work to try to understand the benefits of thatā
Yeah.
ārelative to the overall risk. But certainly opportunities, I mean, part of having both of these molecules in-house could be that opportunity of co-formulationā
Yeah.
āor fixed-dose combinations.
You also have another phase two that's going on right now, your X2 in migraine. I guess as we look to the data next year, what's most compelling about X2 as a target in migraine, in your view?
Yeah, I think X2's been very favorable from a migraine standpoint, just based on the biology that we've generated. So we've done a lot of this work in collaboration with a couple folks over at University of Texas. And I think it's kind of culmination of a bunch of data sets coming together. So one being the kind of recognition that these neuropeptides are key in migraine. So things like substance P, VIP, and PACAP. All three have been in humans, they've dosed them IV, kind of in challenge-type studies.
Yeah.
All three can independently cause migraine phenotypes in humans. I think it highlights the causative nature of these neuropeptides in driving migraine phenotypes. There's also been some pharmacological intervention that's been looked at. Lundbeck, for example, has a PACAP antibody that's shown some nice efficacy in migraine, again, highlighting that interaction with that. There was a study done by Amgen some years ago where they tried to target what they thought was the receptor for PACAP or the relevant receptor, PAC1, showed no efficacy. That was noteworthy. I think that kind of set on a search for what is the kind of putative receptor for these neuropeptides that could be driving migraine.
We've certainly done a lot of knockout studies and knockin studies with X2 and shown that you can mitigate the migraine phenotype in mice when you knock out the mouse ortholog of X2 to PACAP, VIP, and substance P. I think it's creating that relationship between those neuropeptides and X2. We've done similar things with knocking animals and blocking that with 756, our molecule. Ultimately, we needed to go to the clinic to try to see where the effect lies, and that's the study we have ongoing.
From those animal models, is it clear that X2 is the only receptor for PACAP that matters in migraine? That's the big question, right? As you sort of draw the line between the Lundbeck antibody efficacy maybe being a little bit less strong and sort of what exactly PACAP is binding to, right?
Yeah. I think we've ruled out a few things, and we've ruled out that there is a role for X2.
Sure.
But other than that, I think that's where the resolution is right now.
Yeah. Okay. Talk about your phase two study and what does a good outcome look like for you to move forward into a larger pivotal program there?
Yeah, I think the study is right-sized and well set up. I think if we're able to show a 1.5 or so day improvement in monthly migraine days, that would be very well supportive of us going to a later stage study. I think that the market in migraine is desperate for new mechanisms. Chronic migraine sufferers kind of on average suffers 15 migraine days, but the existing treatment landscape is in that one to two days of improvement. We think certainly that we have opportunity to do better than that, but anything in and around that range would be a success.
And importantly, the study is enrolling really well and on track, and I think that there's a lot of interest from the KOL community, and in particular, the key opinion leaders who have been strong advocates of X2 are the ones who have been driving that enrollment. It hasn't just been us beating the drum. It's been the community that says, Hey, we think there's a unique opportunity here for an oral to introduce something new into a treatment landscape that's largely been dominated by the CGRPs for the last decade. And obviously, the introduction of Botox has also done well there. But in reality, the relief is not that great for the patients and the sufferers.
You had with the highest doses in CSU and AD some transaminase elevations, and you are dosing a little bit lower here in migraine. I guess, how has the safety profile been so far? Are you confident that you are not going to run into any safety issues in this study?
Yeah. So I will cover the first part, and then, Jeegar, maybe you weigh in. I think the good news that came out of the prior studies with this molecule was that we have absolutely got doses that are safe and that we believe can be carried forward, and we do not anticipate any of those issues. The signals that we did see were at the highest doses that are no longer being studied. And in fact, at all of the doses that we have moved forward, the safety has been pristine.
Is this enough target coverage here?
Absolutely enough target coverage. So we cover it fully sufficient, and we have done some distribution studies to understand what levels get into the areas of interest, the meningeal space and the trigeminal neuron specifically. I think it is also just great to highlight, we have significant patient experience now at the dose levels that we are testing in migraine from our CSU and AD study. So that was one of the upsides of those two studies. Same duration as well. Those were 12-week studies. This is also a 12-week study.
When might you be able to sort of narrow guidance for 2027?
I mean, I think we're well on track for kind of that Q3 2027 timeframe.
Okay.
Obviously, if enrollment continues to go great, that could come forward, but I think we're on track and maybe kind of end of Q1 next year, we'll be able to refine it a little further.
Okay. Any final thoughts?
I think Evommune has, like I said, we've got a really great group of people who are dedicated to attacking chronic inflammatory diseases with a variety of different opportunities. I think we're small, but we're mighty. We are trying to be innovators. We're trying to push the envelope in difficult-to-treat diseases, and we think that if we continue to do that, we'll find opportunities for success across the programs. We're also hyper-focused on the work that we're doing and advancing each of the programs for their own independent relevance. We're also a team with a wonderful track record of going deep with our programs, but also finding opportunities to deliver for our stakeholders. To the extent that those opportunities present themselves, we'll be open and opportunistic.
But in general, I think the last few weeks have been a positive reflection on the team and on the effort, and we're heading in the right direction. I'm really confident that the pipeline we've got right now is one that supports us becoming a really, really relevant inflammatory disease company.
Great. Well, Greg, Jeegar, thanks so much. Always appreciate it.
Thanks, Alex.